PGEN Precigen, Inc.

NASDAQ
$6.10

Precigen, Inc. (PGEN) is expected to report earnings on November 3, 2026, after the market close. The consensus earnings estimate is $0.09 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -13.1% since its last earnings release on August 4, 2026.

Precigen Beat Consensus Estimates
Tuesday, August 4, 2026 · 4:01 PM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 3
Tuesday · 4:05 PM ET
Earnings Whisper
-
vs $0.09
Rev est $47.46M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $6.78

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Precigen, Inc.

Precigen Inc. is a biopharmaceutical company. It specialise in the development of gene and cell therapies for immuno-oncology, autoimmune disorders and infectious diseases. The company's transformative therapeutic platforms, including UltraCAR-T(TM), AdenoVerse(TM) cytokine therapies, multifunctional therapeutics and off-the-shelf AdenoVerse(TM) immunotherapies, as well as ActoBio Therapeutics, Exemplar Genetics and Triple-Gene from our subsidiaries. Precigen Inc., formerly known as Intrexon Corporation, is based in Germantown, Maryland.

Sector

Healthcare

Industry

Biotechnology

Held By 1 ETFs, by dollar flow